Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Hereditary Angioedema Drug market report explains the definition, types, applications, major countries, and major players of the Hereditary Angioedema Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Pharming Group NV
BioCryst Pharmaceuticals Inc
CSL Limited
IBio Inc
Ionis Pharmaceuticals Inc
Shire plc
By Type:
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By End-User:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Hereditary Angioedema Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Hereditary Angioedema Drug Outlook to 2028- Original Forecasts
-
2.2 Hereditary Angioedema Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Hereditary Angioedema Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Hereditary Angioedema Drug Market- Recent Developments
-
6.1 Hereditary Angioedema Drug Market News and Developments
-
6.2 Hereditary Angioedema Drug Market Deals Landscape
7 Hereditary Angioedema Drug Raw Materials and Cost Structure Analysis
-
7.1 Hereditary Angioedema Drug Key Raw Materials
-
7.2 Hereditary Angioedema Drug Price Trend of Key Raw Materials
-
7.3 Hereditary Angioedema Drug Key Suppliers of Raw Materials
-
7.4 Hereditary Angioedema Drug Market Concentration Rate of Raw Materials
-
7.5 Hereditary Angioedema Drug Cost Structure Analysis
-
7.5.1 Hereditary Angioedema Drug Raw Materials Analysis
-
7.5.2 Hereditary Angioedema Drug Labor Cost Analysis
-
7.5.3 Hereditary Angioedema Drug Manufacturing Expenses Analysis
8 Global Hereditary Angioedema Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Hereditary Angioedema Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Hereditary Angioedema Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Hereditary Angioedema Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Hereditary Angioedema Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global C1 Esterase Inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Kallikrein Inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Selective Bradykinin B2 Receptor Antagonist Consumption and Growth Rate (2017-2022)
-
9.2 Global Hereditary Angioedema Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Hereditary Angioedema Drug Market Analysis and Outlook till 2022
-
10.1 Global Hereditary Angioedema Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Hereditary Angioedema Drug Consumption (2017-2022)
-
10.2.2 Canada Hereditary Angioedema Drug Consumption (2017-2022)
-
10.2.3 Mexico Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.2 UK Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.3 Spain Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.4 Belgium Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.5 France Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.6 Italy Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.7 Denmark Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.8 Finland Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.9 Norway Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.10 Sweden Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.11 Poland Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.12 Russia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.3.13 Turkey Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.2 Japan Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.3 India Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.4 South Korea Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.5 Pakistan Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.7 Indonesia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.8 Thailand Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.9 Singapore Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.10 Malaysia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.11 Philippines Hereditary Angioedema Drug Consumption (2017-2022)
-
10.4.12 Vietnam Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.2 Colombia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.3 Chile Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.4 Argentina Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.5 Venezuela Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.6 Peru Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Hereditary Angioedema Drug Consumption (2017-2022)
-
10.5.8 Ecuador Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6.2 Kuwait Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6.3 Oman Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6.4 Qatar Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Hereditary Angioedema Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Hereditary Angioedema Drug Consumption (2017-2022)
-
10.7.2 South Africa Hereditary Angioedema Drug Consumption (2017-2022)
-
10.7.3 Egypt Hereditary Angioedema Drug Consumption (2017-2022)
-
10.7.4 Algeria Hereditary Angioedema Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Hereditary Angioedema Drug Consumption (2017-2022)
-
10.8.2 New Zealand Hereditary Angioedema Drug Consumption (2017-2022)
11 Global Hereditary Angioedema Drug Competitive Analysis
-
11.1 Pharming Group NV
-
11.1.1 Pharming Group NV Company Details
-
11.1.2 Pharming Group NV Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Pharming Group NV Hereditary Angioedema Drug Main Business and Markets Served
-
11.1.4 Pharming Group NV Hereditary Angioedema Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 BioCryst Pharmaceuticals Inc
-
11.2.1 BioCryst Pharmaceuticals Inc Company Details
-
11.2.2 BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Main Business and Markets Served
-
11.2.4 BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 CSL Limited
-
11.3.1 CSL Limited Company Details
-
11.3.2 CSL Limited Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 CSL Limited Hereditary Angioedema Drug Main Business and Markets Served
-
11.3.4 CSL Limited Hereditary Angioedema Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 IBio Inc
-
11.4.1 IBio Inc Company Details
-
11.4.2 IBio Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 IBio Inc Hereditary Angioedema Drug Main Business and Markets Served
-
11.4.4 IBio Inc Hereditary Angioedema Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Ionis Pharmaceuticals Inc
-
11.5.1 Ionis Pharmaceuticals Inc Company Details
-
11.5.2 Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Main Business and Markets Served
-
11.5.4 Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Shire plc
-
11.6.1 Shire plc Company Details
-
11.6.2 Shire plc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Shire plc Hereditary Angioedema Drug Main Business and Markets Served
-
11.6.4 Shire plc Hereditary Angioedema Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
12 Global Hereditary Angioedema Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Hereditary Angioedema Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global C1 Esterase Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Kallikrein Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Selective Bradykinin B2 Receptor Antagonist Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Hereditary Angioedema Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Hereditary Angioedema Drug Market Analysis and Outlook to 2028
-
13.1 Global Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.5 France Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.3 India Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Hereditary Angioedema Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Hereditary Angioedema Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Hereditary Angioedema Drug
-
Figure of Hereditary Angioedema Drug Picture
-
Table Global Hereditary Angioedema Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Hereditary Angioedema Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global C1 Esterase Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Kallikrein Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Selective Bradykinin B2 Receptor Antagonist Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Table North America Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure United States Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure Germany Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure France Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure China Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure India Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table South America Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure Brazil Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure Bahrain Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure Nigeria Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Hereditary Angioedema Drug Consumption by Country (2017-2022)
-
Figure Australia Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Hereditary Angioedema Drug Consumption and Growth Rate (2017-2022)
-
Table Pharming Group NV Company Details
-
Table Pharming Group NV Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pharming Group NV Hereditary Angioedema Drug Main Business and Markets Served
-
Table Pharming Group NV Hereditary Angioedema Drug Product Portfolio
-
Table BioCryst Pharmaceuticals Inc Company Details
-
Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Main Business and Markets Served
-
Table BioCryst Pharmaceuticals Inc Hereditary Angioedema Drug Product Portfolio
-
Table CSL Limited Company Details
-
Table CSL Limited Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Limited Hereditary Angioedema Drug Main Business and Markets Served
-
Table CSL Limited Hereditary Angioedema Drug Product Portfolio
-
Table IBio Inc Company Details
-
Table IBio Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table IBio Inc Hereditary Angioedema Drug Main Business and Markets Served
-
Table IBio Inc Hereditary Angioedema Drug Product Portfolio
-
Table Ionis Pharmaceuticals Inc Company Details
-
Table Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Main Business and Markets Served
-
Table Ionis Pharmaceuticals Inc Hereditary Angioedema Drug Product Portfolio
-
Table Shire plc Company Details
-
Table Shire plc Hereditary Angioedema Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire plc Hereditary Angioedema Drug Main Business and Markets Served
-
Table Shire plc Hereditary Angioedema Drug Product Portfolio
-
Figure Global C1 Esterase Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Kallikrein Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Selective Bradykinin B2 Receptor Antagonist Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Table North America Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure China Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Hereditary Angioedema Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Hereditary Angioedema Drug Consumption Forecast and Growth Rate (2022-2028)
-
